Physician profile
Daniel C Perry
NPI 1710352083
$4,542.10
in general payments reported to CMS, 2019-2025
18 companies · $884 in 2025
The $884 reported for 2025 was more than what 88% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.44 · 2022: $960 · 2023: $1,623 · 2024: $1,048 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.48 |
| Education | $230.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,264.27 | 2021-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $1,112.02 | 2022-2025 | |
| Lilly USA, LLC | $303.26 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $302.68 | 2021-2024 | |
| Ucb, INC. | $212.75 | 2022-2024 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $192.05 | 2022-2025 | Winlevi |
| Amgen INC. | $181.78 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $174.53 | 2022-2024 | |
| Incyte Corporation | $167.61 | 2023-2025 | Opzelura |
| Pfizer INC. | $138.50 | 2023-2025 | |
| Journey Medical Corporation | $124.99 | 2023 | |
| Janssen Scientific Affairs, LLC | $122.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $86.93 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $47.61 | 2025 | Dupixent |
| Verrica Pharmaceuticals INC. | $32.70 | 2024 | Ycanth |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $28.65 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Merz North America, INC. | $25.40 | 2023 | Xeomin |
| Leo Pharma INC. | $23.54 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.